Effect of granulocyte colony-stimulating factor on neutropenia due to chemotherapy for non-Hodgkin's lymphoma

Open Access
Publisher Website
Google Scholar
Abstract
The authors administered recombinant human granulocyte colony‐stimulating factor (rhG‐CSF) to 16 patients with advanced non‐Hodgkin's lymphoma treated with combination chemotherapy. Groups of three to five patients were treated with 50, 100, 200, and 400 μ/m2 per day of rhG‐CSF by intravenous infusion for 14 days, beginning 3 days after chemotherapy. There was a strong linear relationship between the dose and the area under the curve over this dose range. The rhG‐CSF was rapidly cleared from serum, with a mean half‐life of 5.97 hours for the second phase (t1/2). In patients treated with a dose of more than 100 μg/m2 per day, the duration of neutropenia (P < 0.01) and the duration of fever (P < 0.05) were significantly decreased. The rhG‐CSF was well tolerated and the only clinical observation that appeared relating to rhG‐CSF administration was slight bone pain. This study strongly suggests that an optimum dose of rhG‐CSF in patients after chemotherapy is 100 to 200 μg/m2. Our study shows that rhG‐CSF is a clinically useful drug for patients treated with myelosuppressive chemotherapy.

This publication has 15 references indexed in Scilit: